FH Ortho

Who owns FH Ortho?

FH Ortho has Andera Partners on file as a lender through Acto Mezzanine II (2014 vintage), financing since 2014. Its equity owner is not tracked by GP Intel yet.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

About FH Ortho

FH Ortho is a French orthopaedic device company based in Heimsbrunn, in the Alsace region, that designs, manufactures and distributes implants and surgical instruments for surgeons worldwide. Its catalogue spans a full range of joints, including hip, knee and shoulder prostheses alongside cruciate ligament repair, forefoot, hindfoot and spine solutions, positioning it as a broad-line specialist rather than a single-segment supplier. The business traces its orthopaedic activity back to 1964 and employs roughly 200 people, with about 95 percent of its products manufactured in France. It reaches surgeons in more than 45 countries through a network of specialised distribution partners, competing against far larger multinational implant makers by combining French industrial production with a clinician-focused product line.

Ownership journey

FH Ortho grew out of an orthopaedic manufacturing activity established in France in 1964, with the current operating company structured in 2014. In that same year, Andera Partners, through its Acto Mezzanine II sponsorless vehicle, provided mezzanine financing to support the management team and the company's growth agenda, acting as a debt and quasi-equity backer rather than a controlling equity owner. The Acto franchise specialises in sponsorless mezzanine, backing managers who hold or increase their own stake, and FH Ortho fitted that model. Andera Partners exited the investment in 2020 via a trade sale. Consistent with the site's disclosure conventions, the acquiring party following that exit is not named here.

Under PE ownership

The 2014 mezzanine financing was structured to fund growth while keeping the management team in the driver's seat of the business. Over the holding period FH Ortho broadened its implant portfolio across all major joints and deepened its international footprint, building a distribution reach that now extends to more than 45 countries. The company maintained its French industrial base, keeping close to 95 percent of production domestic, and scaled its workforce to around 200 people. This combination of an expanded product range, export-led commercial development and preserved domestic manufacturing set up the platform that changed hands when Andera Partners exited via a trade sale in 2020.